<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089087</url>
  </required_header>
  <id_info>
    <org_study_id>CCFZ533X2101</org_study_id>
    <nct_id>NCT02089087</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects&#xD;
      and intravenous doses in rheumatoid arthritis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Healthy Volunteer only study originally, but after an amendment to protocol,&#xD;
      rheumatoid arthritis patients will be starting 7-Mar-2014 and thus, the protocol is now&#xD;
      registered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2013</start_date>
  <completion_date type="Actual">February 3, 2017</completion_date>
  <primary_completion_date type="Actual">February 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of CFZ533: Area Under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>6 months</time_frame>
    <description>The following PK parameters were determined from the plasma concentration time profile of CFZ533 using a non-compartmental method:&#xD;
AUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval&#xD;
AUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration&#xD;
AUCinf: Area under the plasma concentration-time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of CFZ533: Observed Maximum Plasma Concentration Following Drug Administration (Cmax)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of CFZ533: Systemic Clearance from Plasma (CL)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of CFZ533: Apparent Volume of Distribution (Vss)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CFZ533 immunogenicity</measure>
    <time_frame>6 months</time_frame>
    <description>Determining the presence and measuring amount of anti-CFZ533 antibodies in the blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CFZ533 in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 single dose in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFZ533 in rheumatoid arthritis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 single dose in rheumatoid arthritis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CFZ533</intervention_name>
    <description>Single dose at varying dosage levels depending on treatment assignment</description>
    <arm_group_label>CFZ533 in healthy volunteers</arm_group_label>
    <arm_group_label>CFZ533 in rheumatoid arthritis patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (for healthy volunteers):&#xD;
&#xD;
          1. Healthy male and surgically sterilized or post-menopausal female subjects 18 to 55&#xD;
             years of age (for Cohort 9 only, subjects must be of Chinese descent)&#xD;
&#xD;
          2. Vital signs (systolic and diastolic blood pressure and pulse rate) should be within&#xD;
             normal limits&#xD;
&#xD;
          3. Weight 50-150 kg and a body mass index (BMI) 18-32 kg/m2&#xD;
&#xD;
        Inclusion Criteria (for rheumatoid arthritis patients):&#xD;
&#xD;
          1. Healthy male and surgically sterilized or post-menopausal female subjects 18 to 55&#xD;
             years of age&#xD;
&#xD;
          2. Fulfilled 2010 ACR/EULAR classification criteria for RA per Investigator&#xD;
&#xD;
          3. Treatment with a stable oral RA treatment regimen for ≥ 4 weeks before randomization&#xD;
&#xD;
          4. Systemic corticosteroids allowed if on a stable dose (≤ 10 mg/day of prednisone or&#xD;
             equivalent) ≥ 4 weeks prior to randomization&#xD;
&#xD;
          5. Subjects taking NSAIDs (COX-1 or COX-2 inhibitors) as part of their RA therapy must be&#xD;
             on a stable dose for at least 4 weeks before randomization&#xD;
&#xD;
        Exclusion Criteria (for healthy volunteers):&#xD;
&#xD;
          1. History of hypersensitivity to vaccines, the study drug, or to drugs of similar&#xD;
             chemical classes (i.e., biologic agents)&#xD;
&#xD;
          2. Abnormal hematology, coagulation or inflammatory lab results&#xD;
&#xD;
          3. History or evidence of tuberculosis.&#xD;
&#xD;
        Exclusion Criteria (for rheumatoid arthritis patients):&#xD;
&#xD;
          1. Use of anti-TNF or other biologics in previous 3 months&#xD;
&#xD;
          2. Any intra-articular injection therapy (e.g., corticosteroid, hyaluronan) required for&#xD;
             treatment of acute RA flare within 4 weeks before randomization&#xD;
&#xD;
          3. Previous treatment with a B cell-depleting biologic agent or any other&#xD;
             immunomodulatory biologic agent within 5 half-lives (experimental or approved)&#xD;
&#xD;
          4. Current treatment with cyclophosphamide&#xD;
&#xD;
          5. Autoimmune disease other than RA&#xD;
&#xD;
          6. Adult juvenile rheumatoid arthritis&#xD;
&#xD;
          7. RA functional status class IV according to the ACR 1991 revised criteria&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207-5710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16987</url>
    <description>Results for CCFZ533X2101 from the Novartis Trial Results database</description>
  </link>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=283</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis, RA, first-in-human, single ascending dose, safety, tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

